Exelixis Inc (EXEL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $58.36 (-0.22%), Market cap $12.49B, P/E ratio 16.46, 52-week low–high $34.54 ~ $49.71.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an or
Financial statements, price targets, institutional (13F) holdings and related news for Exelixis Inc are updated in real time on BlackAll Trade.
Exelixis Inc trades at $58.36 (-0.22%). Real-time quotes and charts are available on BlackAll Trade.
Exelixis Inc has a market cap of about $12.49B. Its P/E ratio is 16.46.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tab